Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
MSD Urges Swift Rollout of Routine HPV Vaccination for Males in Japan
MSD on July 28 renewed its call for Japan to introduce routine HPV vaccination for males as soon as possible, after a Japanese health ministry panel last week deferred a decision on the issue despite years of deliberations. The company…
To read the full story
Related Article
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- MHLW Vaccine Panel Advances Mumps, RSV, HPV Discussions
July 23, 2026
- MSD Japan Chief Voices Regret over Delay in Routine HPV Shots for Males
November 10, 2025
BUSINESS
- Lenvima-Welireg Combo Gets US Nod for Advanced RCC
September 28, 2026
- Daiichi Sankyo Pulls US Filing for B7-H3 ADC in SCLC
September 28, 2026
- Narcolepsy Diagnosis Still Takes Nearly 9 Years in Japan: Expert
September 28, 2026
- Japan OTC Market Down for 6th Straight Month in August: Intage
September 28, 2026
- IHH Unit Appeals Dismissal of 203 Billion Yen Daiichi Sankyo Suit
September 28, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…